Dr. Alon Yaar, DVM, MBA
Dr. Yaar has extensive hands-on experience in leading R&D in biotechnology, pharmaceuticals and medical devices from very early research stages to production and advanced clinical trials. Alon is a serial entrepreneur with proven management skills and a successful track record. Prior to joining KidneyCure, he founded and served as CEO and COO of NeuroDerm (NASDAQ:NDRM), acquired by Mitsubishi Tanabe in 2017 in a $1.1 billion deal. Alon was also Founder and Board Member of Touch Brain Ltd., Neuroptic Ltd., and Science in Action Ltd.
Inna Martin, BA, MBA
Head of Business Development
Mrs. Martin brings more than 17 years of experience in healthcare innovation and Venture Capital fields. Prior to joining KidneyCure, Inna served as an Investment Director at RMI Partners VC, as well as a Member of the Board of ReVision Optics Inc., Ocunnexus Inc., and Ocon Medical Ltd. She also served as a strategic business development and financial consultant to Israel’s leading biomed and pharma-focused Venture Capital firms and companies including NASDAQ traded companies in the US and Canada, in addition to TASE traded biotech and medtech companies.
Dr. Masha Simanovsky, PhD
Dr. Simanovsky brings to KidneyCure 20 years of hands on experience in the research and development of innovative cell therapies, including development of tissue culture, transfection, cell selection, and proliferation assay development. Prior to joining Kidneycure, Masha served as Project Manager at Solubest Ltd., Researcher at the Laboratory of Molecular Immunobiology, Bone Marrow Transplantation Department, Sheba Medical Center, and Researcher at Orgenix Ltd., one the pioneering biotech companies and great success stories of the Israeli biotech industry.
Prof. Benjamin Dekel, MD, PhD
Chief Scientific and Medical Advisor
Avraham Hermon, MA
Mr. Hermon is an Israeli Patent Attorney and a US Patent Agent. He has over 15 years of experience in leading patent firms and as in-house counsel supporting the intellectual property needs of companies and universities in a variety of fields including innovative pharmaceuticals, biotech and medical devices. Before joining KidneyCure, Avraham served as Senior Manager at Teva Pharmaceutical Industries Global Patent Group, Patent Attorney and Director of Pharmaceuticals and Biotechnology, A.C. Entis-IP Ltd., and IP Director at Youdim Pharmaceuticals Ltd.
Prof. Dekel is a world renowned authority in Nephrology, human renal progenitor cells and renal regenerative medicine. The scientific basis and motivation for KidneyCure was created by Prof. Dekel in his research laboratory at the Sheba Medical Center, Israel's largest and leading medical center. The author of more than 100 scientific publications and the principal inventor of KidneyCure's core cellular technologies, Prof. Dekel currently serves as the Head of the Paediatric Stem Cell Research Institute and Director of the Division of Paediatric Nephrology Edmond & Lily Safra Children's Hospital at Sheba. He is also a Full Professor of Pediatrics, Human Genetics and Biochemistry at Sackler School of Medicine, Tel Aviv University and the President of Israel Stem Cell Society.
Dr. Walter Wasser, MD
Dr. Wasser is an Adult Nephrologist with more than 35 years of clinical experience at leading New York medical centers. Dr. Wasser served as Chief of Nephrology for Manhattan hospitals where he was responsible for the establishment of state-of-the-art dialysis centers. After his relocation to Israel, he served as a Senior Adult Nephrologist at Maayne HaYeshua Medical Center in Bnei Braq. Dr. Wasser instructs medical residents and is the author of over 40 publications.
Dr. Sabina Glozman, PhD, MEI
Dr. Glozman has 20 years of serial entrepreneurship and executive management experience in translation of research projects towards GLP, GMP and GCP-compliant product development pathways. Sabina has a proven track record in BioPharma and Life Science product development consulting fields. As an Entrepreneur in Residence at the Technion Institute of Technology, Haifa, Israel she was responsible for structuring the Accelta-Ajinomoto deal. She also lead business and strategic consulting projects at the Ben Gurion University and Biotechnology Institute, Be’er Sheva, Haifa University, Goji Ltd. and Immune Therapeutics Inc. Prior to joining KidneyCure, Sabina served as the CEO of Solubest Ltd., and VP of Business Development at Protalix Ltd. (PLX:US NYSE MKT).